Last reviewed · How we verify
Brentuximab Vedotin for Injection
Brentuximab vedotin targets CD30, a protein found on the surface of certain cancer cells, and delivers a toxic agent to these cells.
Brentuximab vedotin targets CD30, a protein found on the surface of certain cancer cells, and delivers a toxic agent to these cells. Used for Hodgkin lymphoma, Systemic anaplastic large cell lymphoma.
At a glance
| Generic name | Brentuximab Vedotin for Injection |
|---|---|
| Sponsor | Children's Cancer Group, China |
| Drug class | Monoclonal antibody-drug conjugate |
| Target | CD30 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of activated lymphocytes, including Hodgkin and non-Hodgkin lymphoma cells. Brentuximab vedotin is a monoclonal antibody-drug conjugate that binds to CD30 and delivers the toxic agent monomethyl auristatin E (MMAE) to these cells, leading to cell death.
Approved indications
- Hodgkin lymphoma
- Systemic anaplastic large cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
Key clinical trials
- Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment (PHASE2, PHASE3)
- A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |